$JAZZ Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Jazz Pharmaceuticals plc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Jazz Pharmaceuticals plc. Get notifications about new insider transactions in Jazz Pharmaceuticals plc for free.
Page: < prev 1 ... 5 6 7 8 9 10 11 12 13 ... 14 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | Keegan Fintan | EVP, Technical Oper ... | Grant | A | 0.00 | 7,500 | 0 | 43,912 | 36.4 K to 43.9 K (+20.60 %) |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP and General Cou ... | Option Exercise | A | 166.62 | 600 | 99,972 | 600 | |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP and General Cou ... | Option Exercise | A | 166.62 | 19,400 | 3,232,428 | 19,400 | |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP and General Cou ... | Grant | A | 0.00 | 10,000 | 0 | 58,682 | 48.7 K to 58.7 K (+20.54 %) |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | A | 166.62 | 600 | 99,972 | 600 | |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | A | 166.62 | 65,400 | 10,896,948 | 65,400 | |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Grant | A | 0.00 | 33,000 | 0 | 623,332 | 590.3 K to 623.3 K (+5.59 %) |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Gift | G | 0.00 | 10,422 | 0 | 590,332 | 600.8 K to 590.3 K (-1.73 %) |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 158.36 | 25,000 | 3,959,000 | 600,754 | 625.8 K to 600.8 K (-4.00 %) |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Option Exercise | A | 166.62 | 600 | 99,972 | 600 | |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Option Exercise | A | 166.62 | 19,400 | 3,232,428 | 19,400 | |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Grant | A | 0.00 | 10,000 | 0 | 60,024 | 50 K to 60 K (+19.99 %) |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Sell | S | 160.00 | 1,000 | 160,000 | 50,024 | 51 K to 50 K (-1.96 %) |
| Mar 03 2014 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Sell | S | 166.12 | 3,000 | 498,360 | 51,024 | 54 K to 51 K (-5.55 %) |
| Feb 27 2014 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Option Exercise | M | 7.35 | 10,204 | 74,999 | 0 | |
| Feb 27 2014 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Buy | M | 7.35 | 10,204 | 74,999 | 134,925 | 124.7 K to 134.9 K (+8.18 %) |
| Feb 14 2014 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Sell | S | 157.00 | 2,000 | 314,000 | 124,721 | 126.7 K to 124.7 K (-1.58 %) |
| Feb 12 2014 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Option Exercise | M | 46.83 | 2,560 | 119,885 | 37,702 | |
| Feb 12 2014 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Sell | S | 152.83 | 2,560 | 391,245 | 44,777 | 47.3 K to 44.8 K (-5.41 %) |
| Feb 12 2014 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Buy | M | 46.83 | 2,560 | 119,885 | 47,337 | 44.8 K to 47.3 K (+5.72 %) |
| Jan 10 2014 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Sell | S | 131.82 | 2,000 | 263,640 | 126,721 | 128.7 K to 126.7 K (-1.55 %) |
| Dec 13 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Sell | S | 120.50 | 3,000 | 361,500 | 128,721 | 131.7 K to 128.7 K (-2.28 %) |
| Dec 11 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Option Exercise | M | 46.83 | 1,325 | 62,050 | 40,262 | |
| Dec 11 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Sell | S | 117.80 | 1,325 | 156,085 | 44,777 | 46.1 K to 44.8 K (-2.87 %) |
| Dec 11 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Buy | M | 46.83 | 1,325 | 62,050 | 46,102 | 44.8 K to 46.1 K (+2.96 %) |
| Nov 15 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Sell | S | 100.88 | 3,000 | 302,640 | 131,372 | 134.4 K to 131.4 K (-2.23 %) |
| Nov 13 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Option Exercise | M | 46.83 | 2,373 | 111,128 | 41,587 | |
| Nov 13 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Sell | S | 98.50 | 2,373 | 233,741 | 44,405 | 46.8 K to 44.4 K (-5.07 %) |
| Nov 13 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Buy | M | 46.83 | 2,373 | 111,128 | 46,778 | 44.4 K to 46.8 K (+5.34 %) |
| Oct 16 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Option Exercise | M | 46.83 | 5,000 | 234,150 | 43,960 | |
| Oct 16 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Sell | S | 83.31 | 600 | 49,986 | 44,405 | 45 K to 44.4 K (-1.33 %) |
| Oct 16 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Sell | S | 82.53 | 4,400 | 363,132 | 45,005 | 49.4 K to 45 K (-8.91 %) |
| Oct 16 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Buy | M | 46.83 | 5,000 | 234,150 | 49,405 | 44.4 K to 49.4 K (+11.26 %) |
| Oct 11 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Sell | S | 83.10 | 3,000 | 249,300 | 134,372 | 137.4 K to 134.4 K (-2.18 %) |
| Oct 10 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 88.58 | 4,000 | 354,320 | 625,647 | 629.6 K to 625.6 K (-0.64 %) |
| Sep 13 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Sell | S | 87.52 | 3,000 | 262,560 | 137,372 | 140.4 K to 137.4 K (-2.14 %) |
| Sep 10 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 87.59 | 5,000 | 437,950 | 629,647 | 634.6 K to 629.6 K (-0.79 %) |
| Sep 10 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Option Exercise | M | 46.83 | 5,000 | 234,150 | 48,960 | |
| Sep 10 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Sell | S | 87.11 | 5,000 | 435,550 | 44,405 | 49.4 K to 44.4 K (-10.12 %) |
| Sep 10 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Buy | M | 46.83 | 5,000 | 234,150 | 49,405 | 44.4 K to 49.4 K (+11.26 %) |
| Sep 04 2013 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Sell | S | 88.16 | 1,000 | 88,160 | 52,736 | 53.7 K to 52.7 K (-1.86 %) |
| Sep 04 2013 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Sell | S | 87.62 | 2,000 | 175,240 | 21,075 | 23.1 K to 21.1 K (-8.67 %) |
| Aug 14 2013 | JAZZ | Jazz Pharmaceutica ... | Keegan Fintan | EVP, Technical Oper ... | Sell | S | 81.40 | 6,874 | 559,544 | 36,412 | 43.3 K to 36.4 K (-15.88 %) |
| Aug 14 2013 | JAZZ | Jazz Pharmaceutica ... | Keegan Fintan | EVP, Technical Oper ... | Sell | S | 81.86 | 580 | 47,479 | 43,286 | 43.9 K to 43.3 K (-1.32 %) |
| Aug 14 2013 | JAZZ | Jazz Pharmaceutica ... | Keegan Fintan | EVP, Technical Oper ... | Sell | S | 80.83 | 1,212 | 97,966 | 43,866 | 45.1 K to 43.9 K (-2.69 %) |
| Aug 14 2013 | JAZZ | Jazz Pharmaceutica ... | Keegan Fintan | EVP, Technical Oper ... | Sell | S | 59.00 | 3,008 | 177,472 | 45,078 | 48.1 K to 45.1 K (-6.26 %) |
| Aug 14 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Sell | S | 81.02 | 3,000 | 243,060 | 140,372 | 143.4 K to 140.4 K (-2.09 %) |
| Aug 14 2013 | JAZZ | Jazz Pharmaceutica ... | Winningham Rick E | Director | Sell | S | 81.86 | 1,070 | 87,590 | 41,087 | 42.2 K to 41.1 K (-2.54 %) |
| Aug 14 2013 | JAZZ | Jazz Pharmaceutica ... | Sohn Catherine A. | Director | Sell | S | 81.02 | 640 | 51,853 | 5,610 | 6.3 K to 5.6 K (-10.24 %) |
| Aug 14 2013 | JAZZ | Jazz Pharmaceutica ... | MOMTAZEE JAMES C | Director | Sell | S | 81.86 | 1,070 | 87,590 | 17,315 | 18.4 K to 17.3 K (-5.82 %) |
| Aug 14 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Sell | S | 81.86 | 1,070 | 87,590 | 3,430 | 4.5 K to 3.4 K (-23.78 %) |
| Aug 14 2013 | JAZZ | Jazz Pharmaceutica ... | BERNS PAUL L | Director | Sell | S | 81.86 | 1,070 | 87,590 | 3,430 | 4.5 K to 3.4 K (-23.78 %) |
| Aug 13 2013 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Payment of Exercise | F | 80.88 | 1,409 | 113,960 | 23,075 | 24.5 K to 23.1 K (-5.75 %) |
| Aug 13 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Option Exercise | M | 46.83 | 7,500 | 351,225 | 54,140 | |
| Aug 13 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Sell | S | 80.77 | 7,500 | 605,775 | 44,405 | 51.9 K to 44.4 K (-14.45 %) |
| Aug 13 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Buy | M | 46.83 | 7,500 | 351,225 | 51,905 | 44.4 K to 51.9 K (+16.89 %) |
| Aug 13 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Payment of Exercise | F | 80.88 | 3,288 | 265,933 | 44,405 | 47.7 K to 44.4 K (-6.89 %) |
| Aug 13 2013 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP and General Cou ... | Payment of Exercise | F | 80.88 | 3,505 | 283,484 | 48,333 | 51.8 K to 48.3 K (-6.76 %) |
| Aug 13 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Payment of Exercise | F | 80.88 | 3,464 | 280,168 | 143,372 | 146.8 K to 143.4 K (-2.36 %) |
| Aug 13 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 81.86 | 5,000 | 409,300 | 634,647 | 639.6 K to 634.6 K (-0.78 %) |
| Aug 13 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Payment of Exercise | F | 80.88 | 13,044 | 1,054,999 | 639,647 | 652.7 K to 639.6 K (-2.00 %) |
| Aug 13 2013 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Payment of Exercise | F | 80.88 | 3,310 | 267,713 | 53,736 | 57 K to 53.7 K (-5.80 %) |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | Winningham Rick E | Director | Option Exercise | A | 81.76 | 4,500 | 367,920 | 4,500 | |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | Winningham Rick E | Director | Grant | A | 0.00 | 2,250 | 0 | 42,157 | 39.9 K to 42.2 K (+5.64 %) |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | Sohn Catherine A. | Director | Option Exercise | A | 81.76 | 4,500 | 367,920 | 4,500 | |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | Sohn Catherine A. | Director | Grant | A | 0.00 | 2,250 | 0 | 6,250 | 4 K to 6.3 K (+56.25 %) |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | MOMTAZEE JAMES C | Director | Option Exercise | A | 81.76 | 4,500 | 367,920 | 4,500 | |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | MOMTAZEE JAMES C | Director | Grant | A | 0.00 | 2,250 | 0 | 18,385 | 16.1 K to 18.4 K (+13.94 %) |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | BERNS PAUL L | Director | Option Exercise | A | 81.76 | 4,500 | 367,920 | 4,500 | |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | BERNS PAUL L | Director | Grant | A | 0.00 | 2,250 | 0 | 4,500 | 2.3 K to 4.5 K (+100.00 %) |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Option Exercise | A | 81.76 | 4,500 | 367,920 | 4,500 | |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Grant | A | 0.00 | 2,250 | 0 | 4,500 | 2.3 K to 4.5 K (+100.00 %) |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | Mulligan Seamus | Director | Option Exercise | A | 81.76 | 4,500 | 367,920 | 4,500 | |
| Aug 12 2013 | JAZZ | Jazz Pharmaceutica ... | Mulligan Seamus | Director | Grant | A | 0.00 | 2,250 | 0 | 2,005,555 | 2 M to 2 M (+0.11 %) |
| Aug 09 2013 | JAZZ | Jazz Pharmaceutica ... | O'Keefe Kenneth W | Director | Option Exercise | A | 81.76 | 4,500 | 367,920 | 4,500 | |
| Aug 09 2013 | JAZZ | Jazz Pharmaceutica ... | O'Keefe Kenneth W | Director | Sell | S | 81.32 | 261,212 | 21,241,760 | 0 | 261.2 K to 0 (-100.00 %) |
| Aug 09 2013 | JAZZ | Jazz Pharmaceutica ... | O'Keefe Kenneth W | Director | Grant | A | 0.00 | 2,250 | 0 | 4,500 | 2.3 K to 4.5 K (+100.00 %) |
| Aug 02 2013 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Sell | S | 76.22 | 2,000 | 152,440 | 57,046 | 59 K to 57 K (-3.39 %) |
| Jul 12 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Sell | S | 72.40 | 3,000 | 217,200 | 146,836 | 149.8 K to 146.8 K (-2.00 %) |
| Jul 10 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 73.30 | 5,000 | 366,500 | 652,691 | 657.7 K to 652.7 K (-0.76 %) |
| Jun 11 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 68.33 | 5,000 | 341,650 | 657,691 | 662.7 K to 657.7 K (-0.75 %) |
| Jun 04 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | M | 11.48 | 1,452 | 16,669 | 13,791 | |
| Jun 04 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Buy | M | 11.48 | 1,452 | 16,669 | 662,691 | 661.2 K to 662.7 K (+0.22 %) |
| May 23 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 60.00 | 1,000 | 60,000 | 660,643 | 661.6 K to 660.6 K (-0.15 %) |
| May 22 2013 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Sell | S | 58.54 | 1,000 | 58,540 | 58,769 | 59.8 K to 58.8 K (-1.67 %) |
| May 15 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 58.52 | 4,000 | 234,080 | 661,643 | 665.6 K to 661.6 K (-0.60 %) |
| May 13 2013 | JAZZ | Jazz Pharmaceutica ... | RIEDEL NORBERT G | Director | Option Exercise | A | 55.28 | 8,000 | 442,240 | 8,000 | |
| May 13 2013 | JAZZ | Jazz Pharmaceutica ... | RIEDEL NORBERT G | Director | Grant | A | 0.00 | 4,000 | 0 | 4,000 | 0 to 4 K |
| May 13 2013 | JAZZ | Jazz Pharmaceutica ... | McSharry Heather Ann | Director | Option Exercise | A | 55.28 | 8,000 | 442,240 | 8,000 | |
| May 13 2013 | JAZZ | Jazz Pharmaceutica ... | McSharry Heather Ann | Director | Grant | A | 0.00 | 4,000 | 0 | 4,000 | 0 to 4 K |
| May 13 2013 | JAZZ | Jazz Pharmaceutica ... | Gray Peter | Director | Option Exercise | A | 55.28 | 8,000 | 442,240 | 8,000 | |
| May 13 2013 | JAZZ | Jazz Pharmaceutica ... | Gray Peter | Director | Grant | A | 0.00 | 4,000 | 0 | 4,000 | 0 to 4 K |
| May 06 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 60.00 | 1,000 | 60,000 | 665,643 | 666.6 K to 665.6 K (-0.15 %) |
| Apr 11 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 54.52 | 4,000 | 218,080 | 666,643 | 670.6 K to 666.6 K (-0.60 %) |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | M | 11.48 | 2,177 | 24,992 | 15,243 | |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | M | 1.25 | 182 | 228 | 0 | |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | M | 7.96 | 7,040 | 56,038 | 0 | |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | M | 19.37 | 12,583 | 243,733 | 0 | |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | M | 45.27 | 5,299 | 239,886 | 0 | |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | M | 30.18 | 5,299 | 159,924 | 0 | |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | M | 15.09 | 15,902 | 239,961 | 0 | |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Buy | M | 11.48 | 2,177 | 24,992 | 670,643 | 668.5 K to 670.6 K (+0.33 %) |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Buy | M | 1.25 | 182 | 228 | 668,466 | 668.3 K to 668.5 K (+0.03 %) |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Buy | M | 7.96 | 7,040 | 56,038 | 668,284 | 661.2 K to 668.3 K (+1.06 %) |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Buy | M | 19.37 | 12,583 | 243,733 | 661,244 | 648.7 K to 661.2 K (+1.94 %) |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Buy | M | 45.27 | 5,299 | 239,886 | 648,661 | 643.4 K to 648.7 K (+0.82 %) |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Buy | M | 30.18 | 5,299 | 159,924 | 643,362 | 638.1 K to 643.4 K (+0.83 %) |
| Mar 22 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Buy | M | 15.09 | 15,902 | 239,961 | 638,063 | 622.2 K to 638.1 K (+2.56 %) |
| Mar 12 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 60.00 | 1,000 | 60,000 | 622,161 | 623.2 K to 622.2 K (-0.16 %) |
| Mar 12 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 59.48 | 4,000 | 237,920 | 623,161 | 627.2 K to 623.2 K (-0.64 %) |
| Mar 12 2013 | JAZZ | Jazz Pharmaceutica ... | KKR JP III LLC | 10% Owner | Sell | S | 58.28 | 15,865 | 924,612 | 7,888 | 23.8 K to 7.9 K (-66.79 %) |
| Mar 12 2013 | JAZZ | Jazz Pharmaceutica ... | KKR JP III LLC | 10% Owner | Sell | S | 58.28 | 3,734,135 | 217,625,388 | 3,185,058 | 6.9 M to 3.2 M (-53.97 %) |
| Mar 12 2013 | JAZZ | Jazz Pharmaceutica ... | KKR Fund Holdings L.P. | 10% Owner | Sell | S | 58.28 | 15,865 | 924,612 | 7,888 | 23.8 K to 7.9 K (-66.79 %) |
| Mar 12 2013 | JAZZ | Jazz Pharmaceutica ... | KKR Fund Holdings L.P. | 10% Owner | Sell | S | 58.28 | 3,734,135 | 217,625,388 | 3,185,058 | 6.9 M to 3.2 M (-53.97 %) |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Option Exercise | A | 59.13 | 750 | 44,348 | 750 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Option Exercise | A | 59.13 | 11,250 | 665,213 | 11,250 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Grant | A | 0.00 | 6,000 | 0 | 23,888 | 17.9 K to 23.9 K (+33.54 %) |
| Mar 12 2013 | JAZZ | Jazz Pharmaceutica ... | O'Keefe Kenneth W | Director | Sell | S | 58.28 | 400,000 | 23,312,000 | 261,212 | 661.2 K to 261.2 K (-60.49 %) |
| Mar 07 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Sell | S | 58.28 | 15,720 | 916,162 | 15,422 | 31.1 K to 15.4 K (-50.48 %) |
| Mar 07 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Sell | S | 58.28 | 784,280 | 45,707,838 | 768,670 | 1.6 M to 768.7 K (-50.50 %) |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Option Exercise | A | 59.13 | 1,563 | 92,420 | 1,563 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Option Exercise | A | 59.13 | 23,437 | 1,385,830 | 23,437 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Tobias Jeffrey K | EVP, Research & Dev ... | Grant | A | 0.00 | 12,500 | 0 | 47,500 | 35 K to 47.5 K (+35.71 %) |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Option Exercise | A | 59.13 | 1,691 | 99,989 | 1,691 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Option Exercise | A | 59.13 | 25,809 | 1,526,086 | 25,809 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & Chief Commerc ... | Grant | A | 0.00 | 13,750 | 0 | 59,769 | 46 K to 59.8 K (+29.88 %) |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Keegan Fintan | EVP, Technical Oper ... | Option Exercise | A | 59.13 | 25,000 | 1,478,250 | 25,000 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Keegan Fintan | EVP, Technical Oper ... | Grant | A | 0.00 | 12,500 | 0 | 48,086 | 35.6 K to 48.1 K (+35.13 %) |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP and General Cou ... | Option Exercise | A | 59.13 | 1,691 | 99,989 | 1,691 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP and General Cou ... | Option Exercise | A | 59.13 | 30,309 | 1,792,171 | 30,309 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP and General Cou ... | Grant | A | 0.00 | 16,000 | 0 | 51,419 | 35.4 K to 51.4 K (+45.17 %) |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Option Exercise | A | 59.13 | 1,691 | 99,989 | 1,691 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Option Exercise | A | 59.13 | 30,309 | 1,792,171 | 30,309 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Grant | A | 0.00 | 16,000 | 0 | 149,417 | 133.4 K to 149.4 K (+11.99 %) |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Mulligan Seamus | Director | Option Exercise | A | 59.13 | 4,500 | 266,085 | 4,500 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Mulligan Seamus | Director | Sell | S | 58.28 | 425,000 | 24,769,000 | 2,003,305 | 2.4 M to 2 M (-17.50 %) |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | Mulligan Seamus | Director | Grant | A | 0.00 | 2,250 | 0 | 2,428,305 | 2.4 M to 2.4 M (+0.09 %) |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | A | 59.13 | 1,691 | 99,989 | 1,691 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Option Exercise | A | 59.13 | 123,309 | 7,291,261 | 123,309 | |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Grant | A | 0.00 | 50,000 | 0 | 627,161 | 577.2 K to 627.2 K (+8.66 %) |
| Mar 06 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 60.00 | 1,000 | 60,000 | 577,161 | 578.2 K to 577.2 K (-0.17 %) |
| Mar 05 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Option Exercise | M | 7.35 | 44,216 | 324,988 | 10,204 | |
| Mar 05 2013 | JAZZ | Jazz Pharmaceutica ... | FALBERG KATHRYN E | EVP and CFO | Buy | M | 7.35 | 44,216 | 324,988 | 133,417 | 89.2 K to 133.4 K (+49.57 %) |
| Feb 20 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Sell | S | 58.13 | 921 | 53,536 | 31,142 | 32.1 K to 31.1 K (-2.87 %) |
| Feb 20 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Sell | S | 58.13 | 46,451 | 2,700,085 | 1,552,950 | 1.6 M to 1.6 M (-2.90 %) |
| Feb 20 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Sell | S | 59.04 | 4 | 236 | 32,063 | 32.1 K to 32.1 K (-0.01 %) |
| Feb 20 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Sell | S | 58.41 | 375 | 21,905 | 32,067 | 32.4 K to 32.1 K (-1.16 %) |
| Feb 20 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Sell | S | 59.04 | 196 | 11,572 | 1,599,401 | 1.6 M to 1.6 M (-0.01 %) |
| Feb 20 2013 | JAZZ | Jazz Pharmaceutica ... | ENRIGHT PATRICK G | Director | Sell | S | 58.41 | 18,703 | 1,092,476 | 1,599,597 | 1.6 M to 1.6 M (-1.16 %) |
| Feb 13 2013 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman and CEO | Sell | S | 56.23 | 4,000 | 224,920 | 578,161 | 582.2 K to 578.2 K (-0.69 %) |